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Abstract
Objective To assess the association between 5α-reductase inhibitor
(5-ARI) use in men with lower urinary tract symptoms and prostate cancer
risk.
Design Nationwide, population based case-control study for men
diagnosed with prostate cancer in 2007-09 within the Prostate Cancer
data Base Sweden 2.0.
Setting TheNational Prostate Cancer Register, National Patient Register,
census, and Prescribed Drug Register in Sweden, from which we
obtained data on 5-ARI use before date of prostate cancer diagnosis.
Participants 26 735 cases and 133 671 matched controls; five controls
per case were randomly selected from matched men in the background
population. 7815men (1499 cases and 6316 controls) had been exposed
to 5-ARI. 412 men had been exposed to 5-ARI before the diagnosis of
a cancer with Gleason score 8-10.
Main outcome measures Risk of prostate cancer calculated as odds
ratios and 95% confidence intervals by conditional logistic regression
analyses.
Results Risk of prostate cancer overall decreased with an increasing
duration of exposure; men on 5-ARI treatment for more than three years
had an odds ratio of 0.72 (95% confidence interval 0.59 to 0.89; P<0.001
for trend). The same pattern was seen for cancers with Gleason scores
2-6 and score 7 (both P<0.001 for trend). By contrast, the risk of tumours
with Gleason scores 8-10 did not decrease with increasing exposure
time to 5-ARI (for 0-1 year of exposure, odds ratio 0.96 (95% confidence
interval 0.83 to 1.11); for 1-2 years, 1.07 (0.88 to 1.31); for 2-3 years,
0.96 (0.72 to 1.27); for >3 years, 1.23 (0.90 to 1.68); P=0.46 for trend).
Conclusions Men treated with 5-ARI for lower urinary tract symptoms
had a decreased risk of cancer with Gleason scores 2-7, and showed
no evidence of an increased risk of cancer with Gleason scores 8-10
after up to four years’ treatment.
Introduction
Chemoprevention by use of 5α-reductase inhibitors (5-ARI) to
decrease risk of prostate cancer has been investigated in two
large randomised clinical trials. Both these trials showed a
decreased risk of prostate cancer overall in men on
5-ARI—finasteride in the Prostate Cancer Prevention trial
(PCPT) and dutasteride in Reduction by Dutasteride of Prostate
Cancer Events (REDUCE) trial.1 2 These 5-ARIs inhibit the
conversion of testosterone to dihydrotestosterone, the most
potent androgen in the prostate, and thereby decrease androgen
receptor activity.3 There was a 23-25% reduction in risk of
prostate cancer at biopsy for men receiving 5-ARI, compared
with men receiving placebo, in both trials. However, in both
trials, there was also an increased risk of cancer with Gleason
scores 8-10. Based on these findings, The US Food and Drug
Administration (FDA) issued a safety announcement in 2011,
stating that “5 alpha reductase inhibitors may increase the risk
of a more serious form of prostate cancer.”4
The reason for the observed increase in risk in these trials has
not been conclusively elucidated, with different explanations
for these associations put forward.5-11 One theory is that the
increase is real and that 5-ARI promotes prostate cancer with
Gleason scores 8-10, possibly mediated through lower
concentrations of 3β-Adiol and resulting in a decreased
stimulation of the oestrogen β receptor.12 Another theory is that
the association is spurious and caused by detection bias, because
5-ARI facilitates the detection of small foci of tumours with
Gleason scores 8-10.4 To what degree these Gleason 8-10
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cancers are associated with progression and prostate cancer
death has not been studied. However, because 5-ARIs are widely
used in men with lower urinary tract symptoms due to benign
prostatic hyperplasia, there is a need to further elucidate the
association between 5-ARI use and high grade prostate cancer.
The aim of this study was to investigate the association between
the use of 5-ARI for treating lower urinary tract symptoms due
to prostatic enlargement in a clinical setting and prostate cancer
risk, in particular cancer with Gleason scores 8-10.
Methods
Study design
We conducted a case-control study within the nationwide
Prostate Cancer data Base Sweden 2.0, previously described in
detail.13 14
Cases
Cases were found in the National Prostate Cancer Register,
which includes more than 97% of all cases of prostate cancer
in Sweden since 1998, in comparison to the Swedish Cancer
Register, to which registration is mandatory and regulated by
law.15 The National Prostate Cancer Register contains
information on the date of diagnosis; tumour characteristics
according to the tumour, node, metastasis classification; Gleason
score; serum levels of prostate specific antigen at diagnosis;
and primary treatment delivered or decided within six months
after diagnosis. In the Swedish Cancer Register, 28 556 men
had been registered with prostate cancer in 2007-09, of whom
27 863 had been registered in the National Prostate Cancer
Register and 26 735 had a Gleason score registered—that is,
93.6% of all eligible men were included in this register, and
constitute our cases.
Controls
For each case of prostate cancer, a set of five matched controls
was chosen. Eligible controls were all Swedish men free of
prostate cancer at the end of the year of diagnosis of the index
case, who lived in the same county as the case and who were
born in the same year. For men diagnosed with prostate cancer
at age 90 years or over, controls were only matched by year of
birth, owing to the smaller available sample size of putative
controls. A total of 133 671 matched controls were included in
the study.
By use of the unique personal identity number assigned to each
Swedish resident, all cases and controls were linked to several
other nationwide healthcare registries and demographic
databases,16 17 and in this linkage we had no further loss of cases
or controls.
Exposure to 5-ARI
Data on prescriptions for finasteride and dutasteride were
extracted from the Swedish Prescribed Drug Register, which
includes all prescriptions dispensed since July 2005. This
register contains information on the amount and dose of each
drug as well as the date of prescription and dispensing.
Sources of the covariates in the model
As of 1987, the National Patient Register collects information
on inpatient care, including surgical procedures, and discharge
diagnoses coded according to ICD-9 or ICD-10 (international
classification of diseases, 9th or 10th revision). Using data on
discharge diagnoses for the 10 years preceding the prostate
cancer diagnosis of the case, we classified cases and controls
into four categories of comorbidity according to the Charlson
comorbidity index.18 19 From this register, we also obtained
information on the use of transurethral resection of the prostate
in the study population. Since 2001, the register has collected
data from outpatient consultations in specialised care with a
capture rate of about 50% for prostate biopsy procedures guided
by transrectal ultrasound. Therefore, we obtained information
on the use of these procedures before the date of diagnosis for
cases, for both cases and controls. From the Swedish Prescribed
Drug Register, information on all types of α blockers used for
treatment of lower urinary tract symptoms was also retrieved.
The Longitudinal Integration Database for Health Insurance
and Labour Market Studies is a nationwide demographic
database with information on socioeconomic factors. From this
database, we obtained information on the family unit for the
year of diagnosis for the case, classified as married, single with
children, or single with no children. Educational level was
categorised as low (≤9 years of school), middle (10-12 years),
and high (≥13 years); in Sweden, these categories correspond
to mandatory school, high school, and college or university,
respectively.
Statistical analysis
Four separate case-control analyses were performed in this
study. One analysis combined all cases and their matched
controls, and the other three analyses looked at separate Gleason
scores. These Gleason scores were based on the National
Comprehensive Cancer Network’s classification of cancers with
Gleason scores 2-6, 7, and 8-10, for cases and their respective
controls.20 We used univariable and multivariable conditional
logistic regression analysis to model the odds of having prostate
cancer. The conditioning was made on the basis of the control’s
selection criteria. We adjusted the association between prostate
cancer risk and 5-ARI exposure for covariates that were potential
confounding factors including:
• Increased diagnostic activity driven by lower urinary tract
symptoms as indicated by α blocker use; and transurethral
resection of the prostate or increased levels of prostate
specific antigen, as indicated by biopsies.
• Comorbidity before date of diagnosis assessed by the
Charlson comorbidity index, based on discharge diagnoses
in the Swedish inpatient register before the date of
diagnosis for the index case
• Socioeconomic factors assessed by family status and
highest level of education attained.
Results were summarised with odds ratios and 95% confidence
intervals.21 We calculated trend tests using the categories on an
equidistant ordinal scale, and P values were two tailed. Exposure
to 5-ARI was quantified by the number of cumulatively
dispensed defined daily doses and first categorised into any use
(one or more prescriptions dispensed) or no use (no prescriptions
dispensed). Exposure was then separated according to the
duration of defined daily doses (0-1, 1-2, 2-3, and >3 years).22
We analysed finasteride and dutasteride, the two available
5-ARIs, combined because their outcomes were virtually the
same in two clinical trials.1 2 Because there was no reason to
believe that an increasing exposure to α blockers could prevent
or induce prostate cancer, exposure was divided into any use or
no use in the main analysis.
Some men could have had elevated serum levels of prostate
specific antigen or an abnormal digital examination, and
concomitantly had lower urinary tract symptoms; therefore,
they may have undergone an investigation leading to a prostate
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cancer diagnosis in parallel with the initiation of 5-ARI or α
blocker treatment for lower urinary tract symptoms. To avoid
this potential selection bias or confounding by indication, we
used a restriction period. This period was defined as the time
period before prostate cancer diagnosis during which exposure
to 5-ARI, α blockers, transurethral resection of the prostate, and
prostate biopsies was ignored; this restriction period was also
applied for corresponding controls. In addition to a six month
restriction period, we performed sensitivity analyses with
restriction periods of one, three, nine, and 12 months between
the start of 5-ARI or α blockers use and the date of cancer
diagnosis.
The number and the timing of prostate biopsy sessions in relation
to date of diagnosis were divided into five categories:
• No biopsy
• One biopsy session, less than two years before diagnosis
• One biopsy session, two years or more before diagnosis
• Two or more biopsy sessions, with the first less than four
years before diagnosis
• Two or more biopsy sessions, with the first four years or
more before diagnosis.
The statistical analyses were performed by use of the R statistical
program package (version 2.7.2).23
Results
Mean age at inclusion for cases (n=26 735) and controls (n=133
671) combined was 69.3 years (table 1⇓). Menwho had cancers
with Gleason scores 2-6 were younger (mean age 66.6 years)
than those who had cancers with scores 7 (70.0 years) and 8-10
(74.0 years). Treatment with 5-ARI before diagnosis had been
registered in 1499 (5.6%) cases and in 6316 (4.7%) controls. A
substantially larger proportion of patients in the case group than
in the control group had undergone a biopsy before the date of
diagnostic biopsy (9.1% v 2.5%). Cases included slightly higher
proportions of married men, men with high education, and men
with no comorbidities than controls (table 2⇓).
Prostate cancer risk in univariable analysis
In the univariable analysis (table 3⇓), the odds ratio of having
prostate cancer was 0.90 (95% confidence interval 0.73 to 1.10)
for men exposed to 5-ARI for three years or more. The risk of
diagnosis fell for cancers with Gleason scores 2-6 (0.70 (0.53
to 0.93)), but increased slightly for cancers with Gleason scores
8-10 (1.36 (0.99 to 1.85)).
Prostate cancer risk in multivariable analysis
In the multivariable analysis (table 4⇓), all exposure times to
5-ARI combined were associated with a decreased risk of
prostate cancer (overall, odds ratio 0.89 (95% confidence
interval 0.84 to 0.94); with Gleason scores 2-6, 0.88 (0.80 to
0.96); with Gleason score 7, 0.85 (0.77 to 0.94)). However, the
risk was unchanged for cancer with Gleason scores 8-10 (1.01
(0.90 to 1.13)). There was a decrease in risk with an increasing
duration of 5-ARI exposure for all cancers combined in men
receiving 5-ARI treatment for more than three years (0.72 (0.59
to 0.89); P<0.001 for trend; table 4). The same pattern was seen
for risk of cancer with Gleason scores 2-6 (P<0.001 for trend)
and 7 (P<0.001 for trend). By contrast, the risk of tumours with
Gleason scores 8-10 did not decrease with increasing exposure
time (for 0-1 year, odds ratio 0.96 (95% confidence interval
0.83 to 1.11); for 1-2 years, 1.07 (0.88 to 1.31); for 2-3 years,
0.96 (0.72 to 1.27); for >3 years, 1.23 (0.90 to 1.68); P=0.46
for trend; table 4). Men using α blockers had an increased risk
of prostate cancer (1.33 (1.27 to 1.39)); this risk was highest
for tumours with Gleason scores 2-6 (1.60 (1.50 to 1.71)) and
lowest for those with Gleason scores 8-10 (1.06 (0.96 to 1.18)).
Risk estimates for the other risk factors in the multivariable
analyses were similar to those in the univariable analyses.
During the first year of 5-ARI exposure, an increasing duration
of the restriction period was associated with a decreasing risk
of prostate cancer (fig 1⇓). However, the duration of the
restriction period did not alter the association between an
increased duration of exposure to 5-ARI and a decreasing overall
prostate cancer risk. The pattern for α blocker exposure was
different, with an increased risk to be diagnosed with prostate
cancer overall. This raised risk was most pronounced for cancer
with Gleason scores 2-6, less obvious for cancer with Gleason
score 7, and not seen for cancer with Gleason scores 8-10 (fig
2⇓).
Discussion
In this nationwide, population based, case-control study,
increasing duration of exposure to 5-ARI was associated with
a decreased risk of prostate cancer overall, and this decrease
was restricted to cancers with Gleason scores 2-6 and 7. There
was no significant association in risk of cancers with Gleason
scores 8-10. Our data, together with previous studies, suggest
that the net balance between benefit and harm for 5-ARI use is
favourable in men with lower urinary tract symptoms based on
prostatic enlargement.
Strengths and limitations of the study
Our study had some limitations owing to its observational
design. There was no predefined indication or protocol for the
performance of prostate biopsies in our study, we had no data
on serum levels of prostate specific antigen or digital rectal
examinations including prostate size at the start of 5-ARI
exposure, data from routine histopathological assessment were
used for Gleason classification, and our follow-up time was
restricted to amaximumof four years. Furthermore, confounding
by indication was a concern because we could not assume that
men were free of prostate cancer when 5-ARI was initiated.
However, by use of a restriction period, we reduced the risk that
men with prevalent cancer were included in the analysis and
classified as exposed to 5-ARI, thereby creating a falsely
increased risk after a short exposure to 5-ARI. We further
adjusted our risk estimates for covariates that were potential
confounders related to an increased diagnostic activity of
prostatic diseases by including them in themultivariable models.
Strengths of our study design included its large size; 412 men
had been exposed to 5-ARI before the diagnosis of a cancer
with Gleason scores 8-10. By comparison, cancer with Gleason
scores 8-10 was diagnosed in 90 and 29 men in the case groups
in the PCPT and REDUCE trials, respectively.1 2 Another
strength was that we had detailed and complete information on
exposure assessed in daily doses for finasteride, dutasteride,
and α blockers by use of data from the Prescribed Drug Register
before the date of diagnosis. We also had access to
comprehensive information on risk factors for prostate cancer,
including diagnostic intensity in terms of prostate biopsy
sessions, transurethral resection of the prostate, comorbidity,
and socioeconomic factors. The duration of the restriction period
did not alter the association between 5-ARI exposure and risk
of prostate cancer in men who had been exposed to 5-ARI for
more than one year. The use of a restriction period decreased
the selection mechanisms for men in the cases group who had
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undiagnosed clinical prostate cancer and who received 5-ARI
for a short period of time in parallel with a diagnostic
investigation leading to a diagnosis.
Comparison with other studies
Our observational study differed in several important aspects
from previous clinical trials,1 2 and one important difference
was the inclusion criteria and the clinical setting in which the
studies were undertaken. In our study, 5-ARI was used because
of lower urinary tract symptoms, most likely caused by benign
prostatic hyperplasia, and we had little means other than
introducing a restriction period to exclude prevalent cancers. In
the PCPT trial, inclusion criteria included a normal digital rectal
examination and a prostate specific antigen concentration lower
3 ng/mL; in the REDUCE trial, eligible men had a prostate
specific antigen concentration of 2.5-10 ng/ mL and one negative
prostate biopsy session.1 2 In these trials, the majority of cancers
were detected at the end of study since biopsies were preplanned
for all participants (61% in PCPT and 88% in REDUCE), which
led to the detection of many small and probably insignificant
cancers. This endpoint cancer on biopsy at the end of the study
has caused concern, and some authors have questioned the
generalisability of the results from these trials.24 Although we
had no registration on the indication for biopsy, the vast majority
of biopsies in our study were performed for cause—that is, a
clinical indication such as elevated serum levels of prostate
specific antigen or an abnormal digital rectal examination—and
therefore, a much larger proportion of cancers were clinically
significant in our study than in the PCPT and REDUCE trials.
The clinical setting in our study was similar to that in the
combination of avodart and tamsulosin (CombAT) study, in
whichmenwith moderate to severe benign prostatic hyperplasia
were randomised to dutasteride, tamsulosin, or a combination
of both, and risk for prostate cancer was investigated.25 In
CombAT, biopsies were undertaken for cause—that is, for an
abnormal result from an digital rectal examination or increased
serum levels of prostate specific antigen. Dutasteride, alone or
in combination with tamsulosin, was associated with a 40%
relative risk reduction of prostate cancer diagnosis compared
with tamsulosin monotherapy. The risk decreased for cancers
with all Gleason scores, including scores 8-10—in contrast to
our study and the PCPT and REDUCE trials. However, there
were only 24 cancers with scores 8-10, out of a total of 134
prostate cancers in CombAT.
In the recent trial on reduction by dutasteride of clinical
progression events in expectant management (REDEEM), men
with low risk prostate cancers on active surveillance were
randomised to dutasteride or placebo.26 After three years, 54
(38%) of 144 men in the dutasteride group (hazard ratio 0.62
(95% confidence interval 0.43 to 0.89), P=0.009), and 70 (48%)
of 145 controls had had prostate cancer progression (defined as
progression on prostate biopsy or start of treatment for prostate
cancer).
In an observational cohort study performed within the Finnish
prostate cancer screening trial, overall incidence of prostate
cancer was non-significantly decreased in finasteride users
(hazard ratio 0.87 (95% confidence interval 0.63 to 1.19)),
compared with non-users.27 Risk of cancer with Gleason scores
2-6 was significantly decreased among finasteride users (0.59
(0.38 to 0.91)), whereas risk of cancer with scores 7-10 was
non-significantly increased (1.33 (0.77 to 2.30)). By contrast
with our observations, overall risk of prostate cancer was not
increased significantly among α blocker users in the Finnish
study. Our interpretation of the increased risk of prostate cancer
in men on α blockers is that men with lower urinary tract
symptoms have a higher probability of undergoing a prostate
specific antigen test and eventually a prostate biopsy, and
thereby have an increased risk of a prostate cancer diagnosis,
previously described in a Danish nationwide cohort study.28
Globally, data from our study— together with data from the
PCPT, REDUCE, CombAT, REDEEM, and Finnish
studies—indicate that the association between 5-ARI exposure
and risk of low grade prostate cancer is different from that to
high grade cancer.1 2 25-27 In all these studies, a decreased risk of
cancer with Gleason scores 2-6 for men receiving 5-ARI was
observed, but the association has been less consistent for cancer
with Gleason scores 8-10. Both the PCPT and REDUCE trials
reported an increased risk of cancer with Gleason scores 8-10,
whereas our study and the CombAT study did not observe a
significant increase of Gleason score 8-10 cancers in men
receiving 5-ARI treatment for lower urinary tract symptoms.
Treatment with 5-ARI for men with lower urinary tract
symptoms due to prostatic enlargement provides symptom relief
and a decreased risk of surgical procedures.29 30 With these
benefits in mind and the lack of serious side-effects, the net
balance seems favourable for men with lower urinary tract
symptoms treated with 5-ARI.
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Tables
Table 1| Covariate exposure before date of prostate cancer diagnosis for cases and matched controls, according to date of diagnosis for
index case
Gleason score of cancer
8-1072-6Overall
Controls
(n=27 408)
Cases
(n=5482)
Controls
(n=46 425)
Cases
(n=9285)
Controls
(n=59 838)
Cases (n=11
985)
Controls
(n=133 671)
Cases (n=26
735)
Age (years)
74.0 (9.1)74.0 (9.1)70.0 (8.9)70.0 (8.9)66.6 (8.2)66.6 (8.2)69.3 (9.1)69.3 (9.1)Mean (standard
deviation)
5-ARI
25 580 (93.3)5070 (92.5)44 156 (95.1)8809 (94.9)57 619 (96.3)11 357 (94.9)127 355 (95.3)25 236 (94.4)No treatment
Treatment received (exposure period)
1828 (6.7)412 (7.5)2269 (4.9)476 (5.1)2219 (3.7)611 (5.1)6316 (4.7)1499 (5.6)Combined*
974 (3.6)210 (3.8)1249 (2.7)293 (3.2)1325 (2.2)447 (3.7)3548 (2.7)950 (3.6)0-1 year
442 (1.6)107 (2.0)510 (1.1)92 (1.0)491 (0.8)105 (0.9)1443 (1.1)304 (1.1)1-2 years
254 (0.9)52 (0.9)304 (0.7)52 (0.6)233 (0.4)47 (0.4)791 (0.6)151 (0.6)2-3 years
158 (0.6)43 (0.8)206 (0.4)39 (0.4)170 (0.3)12 (0.1)534 (0.4)94 (0.4)>3 years
α blockers
25 459 (92.9)5042 (92.0)43 535 (93.8)8545 (92.0)56 655 (94.7)10 734 (89.7)125 649 (94.0)24 321 (91.0)No treatment
1949 (7.1)440 (8.0)2890 (6.2)740 (8.0)3183 (5.3)1234 (10.3)8022 (6.0)2414 (9.0)Treatment
received
Previous prostate biopsy†
26 652 (97.2)5144 (93.8)45 308 (97.6)8572 (92.3)58 463 (97.7)10 568 (88.3)130 423 (97.6)24 284 (90.8)No previous
biopsy
Previous biopsy undertaken‡
177 (0.6)100 (1.8)288 (0.6)250 (2.7)415 (0.7)571 (4.8)880 (0.7)921 (3.4)1 biopsy, <2
years
403 (1.5)134 (2.4)562 (1.2)223 (2.4)645 (1.1)375 (3.1)1610 (1.2)732 (2.7)1 biopsy, ≥2
years
82 (0.3)58 (1.1)121 (0.3)142 (1.5)167 (0.3)297 (2.5)370 (0.3)497 (1.9)≥2 biopsies, <4
years
94 (0.3)46 (0.8)146 (0.3)98 (1.1)148 (0.2)157 (1.3)388 (0.3)301 (1.1)≥2 biopsies, ≥4
years
Transurethral resection of the prostate
25 770 (94.0)5200 (94.9)44 399 (95.6)8939 (96.3)57 887 (96.7)11 603 (97.0)128 056 (95.8)25 742 (96.3)No resection
1638 (6.0)282 (5.1)2026 (4.4)346 (3.7)1951 (3.3)365 (3.0)5615 (4.2)993 (3.7)Resection
conducted
Data are number or number (%) of individuals unless stated otherwise.
*All exposure times combined.
†Prostate biopsy sessions performed before the diagnostic biopsy session for the case and corresponding date for the control.
‡Biopsies undertaken within specified period before diagnosis.
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Table 2| Socioeconomic factors and comorbidity for cases and matched controls
Gleason score of cancer
8-1072-6Overall
Controls (n=27
408)
Cases
(n=5482)
Controls (n=46
425)
Cases
(n=9285)
Controls (n=59
838)
Cases (n=11
985)
Controls
(n=133 671)
Cases (n=26
735)
Family status
17 495 (63.8)3603 (65.7)30 672 (66.1)6373 (68.6)40 232 (67.2)8620 (72.0)88 399 (66.1)18 596 (69.6)Married
6667 (24.3)1295 (23.6)10 195 (22.0)2062 (22.2)12 677 (21.2)2349 (19.6)29 539 (22.1)5706 (21.3)Single, with
children
3246 (11.8)584 (10.7)5558 (12.0)850 (9.2)6929 (11.6)999 (8.3)15 733 (11.8)2433 (9.1)Single, no
children
Highest attained level of education
4861 (17.7)983 (17.9)9626 (20.7)2105 (22.7)13 702 (22.9)3101 (25.9)28 189 (21.1)6189 (23.1)High
9561 (34.9)1871 (34.1)17 157 (37.0)3470 (37.4)23 128 (38.7)4756 (39.7)49 846 (37.3)10 097 (37.8)Middle
12 986 (47.4)2628 (47.9)19 642 (42.3)3710 (40.0)23 008 (38.5)4111 (34.3)55 636 (41.6)10 449 (39.1)Low or
missing
data
Charlson comorbidity index
15 934 (58.1)3152 (57.5)29 852 (64.3)6235 (67.2)41 830 (69.9)8542 (71.4)87 616 (65.5)17 929 (67.1)0
5306 (19.4)1099 (20.0)8226 (17.7)1624 (17.5)9495 (15.9)1839 (15.4)23 027 (17.2)4562 (17.1)1
3223 (11.8)661 (12.1)4481 (9.7)823 (8.9)4792 (8.0)987 (8.2)12 496 (9.3)2471 (9.2)2
2945 (10.7)570 (10.4)3866 (8.3)603 (6.5)3721 (6.2)600 (5.0)10 532 (7.9)1773 (6.6)≥3
Data are number or number (%) of individuals unless stated otherwise.
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Table 3| Risk of prostate cancer diagnosis in univariable analysis (men exposed to each factor v men not exposed)
Risk of diagnosis, by Gleason score of cancer (odds ratio (95% CI))
8-1072-6Overall
5-ARI
1.001.001.001.00No treatment (reference)
Treatment received (exposure period)
1.08 (0.94 to 1.25)1.16 (1.03 to 1.31)1.40 (1.30 to 1.51)1.32 (1.23 to 1.41)0-1 year
1.21 (0.99 to 1.47)0.91 (0.74 to 1.12)1.00 (0.87 to 1.15)1.06 (0.95 to 1.19)1-2 years
1.04 (0.79 to 1.38)0.87 (0.66 to 1.15)0.94 (0.77 to 1.15)0.97 (0.83 to 1.14)2-3 years
1.36 (0.99 to 1.85)0.95 (0.69 to 1.32)0.70 (0.53 to 0.93)0.90 (0.73 to 1.10)>3 years
α blockers
1.001.001.001.00No treatment
1.13 (1.02 to 1.25)1.28 (1.19 to 1.39)1.93 (1.81 to 2.05)1.50 (1.44 to 1.57)Treatment received
Previous prostate biopsy*
1.001.001.001.00No previous biopsy (reference)
Previous biopsy undertaken†
2.66 (2.15 to 3.29)3.70 (3.24 to 4.22)5.19 (4.75 to 5.67)4.18 (3.91 to 4.47)1 biopsy, <2 years
1.66 (1.39 to 1.99)1.98 (1.73 to 2.28)2.86 (2.57 to 3.18)2.24 (2.08 to 2.42)1 biopsy, ≥2 years
3.10 (2.35 to 4.09)4.63 (3.88 to 5.53)6.04 (5.35 to 6.83)4.93 (4.50 to 5.40)≥2 biopsies, <4 years
2.37 (1.74 to 3.22)3.07 (2.49 to 3.78)4.46 (3.78 to 5.27)3.41 (3.04 to 3.83)≥2 biopsies, ≥4 years
Transurethral resection of the prostate
1.001.001.001.00No resection (reference)
0.86 (0.76 to 0.97)0.86 (0.77 to 0.96)0.94 (0.84 to 1.04)0.89 (0.83 to 0.95)Resection conducted
Family status
1.001.001.001.00Married (reference)
0.95 (0.89 to 1.01)0.97 (0.92 to 1.02)0.87 (0.83 to 0.91)0.92 (0.90 to 0.95)Single, with children
0.88 (0.80 to 0.96)0.75 (0.70 to 0.81)0.69 (0.64 to 0.74)0.75 (0.72 to 0.78)Single, no children
Highest attained level of education
1.001.001.001.00High (reference)
0.97 (0.90 to 1.05)0.93 (0.88 to 0.98)0.91 (0.87 to 0.95)0.93 (0.90 to 0.96)Middle
1.00 (0.93 to 1.08)0.86 (0.82 to 0.91)0.79 (0.75 to 0.83)0.86 (0.83 to 0.89)Low or missing data
Charlson comorbidity index
1.001.001.001.000 (reference)
1.05 (0.97 to 1.12)0.94 (0.89 to 0.99)0.95 (0.90 to 1.00)0.96 (0.93 to 1.00)1
1.04 (0.95 to 1.13)0.87 (0.81 to 0.94)1.00 (0.93 to 1.07)0.96 (0.92 to 1.00)2
0.98 (0.90 to 1.08)0.75 (0.68 to 0.81)0.79 (0.73 to 0.86)0.83 (0.79 to 0.87)≥3
*Prostate biopsy sessions performed before the diagnostic biopsy session for the case and corresponding date for the control.
†Biopsies undertaken within specified period before diagnosis.
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Table 4| Risk of prostate cancer diagnosis in multivariate analysis (men exposed to each factor v men not exposed, adjusted for each
factor)
Risk of diagnosis, by Gleason score of cancer (odds ratio (95% CI))
8-1072-6Overall
5-ARI
1.001.001.001.00No treatment (reference)
Treatment received (exposure period)
1.01 (0.90 to 1.13)0.85 (0.77 to 0.94)0.88 (0.80 to 0.96)0.89 (0.84 to 0.94)Combined*
0.96 (0.83 to 1.11)0.92 (0.81 to 1.04)1.04 (0.93 to 1.15)0.96 (0.90 to 1.03)0-1 year
1.07 (0.88 to 1.31)0.76 (0.62 to 0.95)0.70 (0.57 to 0.86)0.81 (0.72 to 0.91)1-2 years
0.96 (0.72 to 1.27)0.73 (0.55 to 0.97)0.67 (0.50 to 0.90)0.77 (0.65 to 0.90)2-3 years
1.23 (0.90 to 1.68)0.79 (0.57 to 1.10)0.27 (0.15 to 0.48)0.72 (0.59 to 0.89)>3 years
0.46<0.001<0.001<0.001P for trend
α blockers
1.001.001.001.00No treatment (reference)
1.06 (0.96 to 1.18)1.19 (1.10 to 1.29)1.60 (1.50 to 1.71)1.33 (1.27 to 1.39)Treatment received
Previous prostate biopsy†
1.001.001.001.00No previous biopsy (reference)
Previous biopsy undertaken‡
2.69 (2.17 to 3.33)3.65 (3.19 to 4.18)4.71 (4.31 to 5.16)4.01 (3.74 to 4.29)1 biopsy, <2 years
1.70 (1.42 to 2.04)2.10 (1.83 to 2.42)2.84 (2.55 to 3.17)2.30 (2.13 to 2.48)1 biopsy, ≥2 years
3.11 (2.35 to 4.11)4.51 (3.77 to 5.39)5.75 (5.08 to 6.51)4.76 (4.34 to 5.23)≥2 biopsies, <4 years
2.40 (1.76 to 3.28)3.19 (2.59 to 3.94)4.36 (3.69 to 5.16)3.46 (3.07 to 3.89)≥2 biopsies, ≥4 years
Transurethral resection of the prostate
1.001.001.001.00No resection (reference)
0.80 (0.71 to 0.91)0.76 (0.68 to 0.85)0.72 (0.64 to 0.80)0.75 (0.71 to 0.81)Resection conducted
Family status
1.001.001.001.00Married (reference)
0.95 (0.89 to 1.01)0.99 (0.94 to 1.04)0.89 (0.85 to 0.93)0.94 (0.91 to 0.97)Single, with children
0.89 (0.81 to 0.97)0.78 (0.72 to 0.83)0.72 (0.68 to 0.77)0.78 (0.74 to 0.81)Single, no children
Highest attained level of education
1.001.001.001.00High (reference)
0.98 (0.91 to 1.07)0.94 (0.89 to 1.00)0.94 (0.89 to 0.98)0.95 (0.92 to 0.98)Middle
1.02 (0.95 to 1.11)0.89 (0.84 to 0.94)0.84 (0.80 to 0.88)0.89 (0.87 to 0.92)Low or missing data
Charlson comorbidity index
1.001.001.001.000 (reference)
1.05 (0.98 to 1.13)0.94 (0.89 to 1.00)0.97 (0.92 to 1.02)0.98 (0.94 to 1.01)1
1.05 (0.96 to 1.14)0.89 (0.82 to 0.96)1.02 (0.95 to 1.09)0.98 (0.93 to 1.02)2
0.99 (0.90 to 1.09)0.76 (0.70 to 0.83)0.82 (0.76 to 0.90)0.84 (0.80 to 0.89)≥3
*All exposure times combined.
†Prostate biopsy sessions performed before the diagnostic biopsy session for the case and corresponding date for the control.
‡Biopsies undertaken within specified period before diagnosis.
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Figures
Fig 1 Risk of prostate cancer according to time of exposure to 5-ARI and duration of restriction period. Odds ratios from
multivariable model include prescription of α blockers, transurethral resection of the prostate, prostate biopsies, composition
of household, education, and comorbidity
Fig 2 Risk of prostate cancer according to time of exposure to α blockers and duration of restriction period. Odds ratios
frommultivariable model including prescription of 5-ARI, transurethral resection of the prostate, prostate biopsies, composition
of household, education, and comorbidity
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